Epigral (Mid Cap - High Growth) Share Target 2025, 2026 To 2035
|
Epigral Limited |
|||
|
Price: ₹1,713.25 (-3.03%) | ||
| 52 Week Low: ₹931.60 52 Week High: ₹2,406.75 |
|||
| Market Capital: 8,269.2 Crore (Midcap) | |||
| Basic Materials -> Chemicals | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Epigral Share Price Target For 2025
- 1.1.1: Epigral Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Epigral Share Price Target For 2026
- 1.2.1: Epigral Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Epigral Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Epigral Brief Company Overview
- 4: Epigral Financial Performance
- 4.0.1: Is Epigral A Good Buy For Long Term?
Epigral, a Mid Cap company in the Chemicals Industry has delivered 94.3% returns in 3-year showing 30.9% quarterly revenue growth with 12.9% profit margin, making it a High Growth stock.
To predict the Epigral's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Epigral Share Price Target For 2025
The line chart displays the monthly closing prices of Epigral with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Epigral shares in 2025, see the table below.
Epigral Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1980.45 (+15.59%) | Price Action: 23 Sep 2024 Low |
| 2025 Target 2 | 1955.0 (+14.11%) | Price Action: 22 Aug 2024 Low |
| 2025 Target 1 | 1933.65 (+12.86%) | Price Action: 29 Oct 2024 Low |
| Current Price | 1713.25 | Epigral's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1602.93 (-6.44%) | Technical Indicator: MA250 |
| Stop Loss 2 | 1584.0 (-7.55%) | Price Action: 03 Jul 2024 High |
| Stop Loss 3 | 1562.65 (-8.8%) | Price Action: 14 Jan 2025 Low |
Short-Term Technical Outlook
Current Technical Position: Epigral is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹1828.7 serves as the nearest technical reference point.
Historical Returns: 3-month: -19.1% | 6-month: -0.69% | 1-year: +64.63%
Epigral Share Price Target For 2026
The line chart displays the monthly closing prices of Epigral with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Epigral shares in 2026, see the table below.
Epigral Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 2835.27 (+65.48%) | Price Action: Chart |
| 2026 Target 2 | 2782.4 (+62.4%) | Fibonacci Extension Level 123.60% |
| 2026 Target 1 | 2746.3 (+60.29%) | Fibonacci Extension Level 64.90% |
| Current Price | 1713.25 | Epigral's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1475.95 (-13.86%) | Price Action: 01 Jul 2024 High |
| Stop Loss 2 | 1458.95 (-14.85%) | Price Action: 19 Jul 2024 High |
| Stop Loss 3 | 1443.25 (-15.76%) | Price Action: 23 Apr 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Epigral is currently trading at 53.0% of its 52-week range (₹931.6 - ₹2406.75).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +64.63% | 3-year: +94.32% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Epigral Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,713.25 | ||
| 2025 | ₹3,062.70 | +78.76% | ₹3,108.64 |
| 2026 | ₹4,517.66 | +47.5% | ₹4,585.42 |
| 2027 | ₹6,375.04 | +41.11% | ₹6,470.67 |
| 2028 | ₹9,015.39 | +41.41% | ₹9,150.62 |
| 2029 | ₹12,029.33 | +33.43% | ₹12,209.77 |
| 2030 | ₹17,312.58 | +43.91% | ₹17,572.27 |
| 2031 | ₹22,273.94 | +28.65% | ₹22,608.05 |
| 2032 | ₹28,224.30 | +26.71% | ₹28,647.66 |
| 2033 | ₹36,587.82 | +29.63% | ₹37,136.64 |
| 2034 | ₹45,614.94 | +24.67% | ₹46,299.16 |
| 2035 | ₹59,455.47 | +30.34% | ₹60,347.30 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Epigral Brief Company Overview
Epigral Limited: A Leading Chlor-Alkali Producer Epigral Limited, formerly known as Meghmani Finechem Limited, is an established manufacturer and distributor of chlor-alkali and related derivatives in India and globally. Since its inception in 2007, headquartered in Ahmedabad,...
India, the company has gained a strong reputation in the industry. Key Products and Services: Chlorinated polyvinyl chloride (CPVC) resins Epichlorohydrin Chloromethanes Hydrogen peroxide Caustic soda, chlorine, and hydrogen Caustic potash products Market Presence: Epigral serves various sectors, including construction, paints and coatings, water treatment, healthcare, and agriculture, among others. Their products find applications in CPVC pipes and fittings, windmills, agrochemicals, pharmaceuticals, and other industries. Commitment: Epigral Limited is committed to delivering high-quality products and services while adhering to strict safety and environmental standards.Epigral Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 8,269.2 Crore | Market valuation of Epigral's shares. |
| Revenue (TTM) | 2,273.41 Crore | Total revenue generated by Epigral over the past twelve months. |
| Net Income (TTM) | +293.53 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +23.34% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +12.91% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+30.9% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+113.99% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
64.01 | Company's total debt divided by total shareholder equity. |
| Total Debt | 896.36 Crore | Sum of Epigral's current & long-term financial obligations. |
| Total Cash | 6.08 Crore | Total amount of liquid funds available to Epigral. |
| Beta | -0.13 | Beta is less than 1 indicating that the Epigral's price is less volatile than the market. |
Is Epigral A Good Buy For Long Term?
Epigral (market cap: ₹8,269.2 Crore), while showing strong recent performance (115.45% return in the past 12 months, 97.43% YTD), presents a mixed picture for long-term investment. High revenue growth (30.9% QoQ) and a decent profit margin (12.91%) are positive. However, significant debt (₹896.36 Crore) against minimal cash reserves (₹6.08 Crore) raises concerns. The lack of 3- and 5-year return data prevents a complete assessment of its long-term stability. Therefore, it's currently an average buy, requiring further due diligence before a strong recommendation can be made.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
